Login
$INVA
$18.49 -$0.54 (2.84%) Live

$INVA SEC Filings

Filed On Filing
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth

27 Oct 2026 SCHEDULE 13G/A
24 Aug 2026 Form 4: Zhen Marianne, Chief Accounting Officer

Gave up 1,127 shares to cover exercise price or tax ($23.7K)

24 Aug 2026 Form 4: Basso Stephen, Chief Financial Officer

Gave up 558 shares to cover exercise price or tax ($11.7K)

24 Aug 2026 Form 4: Raifeld Pavel, Director

Gave up 1,130 shares to cover exercise price or tax ($23.7K)

05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth

31 Jul 2026 SCHEDULE 13G
22 May 2026 Form 4: Basso Stephen, Chief Financial Officer

Received 1,123 shares as a grant or award · Gave up 559 shares to cover exercise price or tax ($12.4K)

22 May 2026 Form 4: Raifeld Pavel, Director

Received 1,123 shares as a grant or award · Gave up 1,130 shares to cover exercise price or tax ($25.1K)

22 May 2026 Form 4: Zhen Marianne, Chief Accounting Officer

Gave up 1,127 shares to cover exercise price or tax ($25.1K)

20 May 2026 Form 4: Linden Josephine, Director

Received 15,194 shares as a grant or award · Granted 9,166 Non-statutory Stock Option

20 May 2026 Form 3: Linden Josephine, Director

Holds 0 shares of No securities beneficially owned

18 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

13 May 2026 SCHEDULE 13D/A
06 May 2026 10-Q
06 May 2026 8-K: Results of Operations and Financial Condition

Generated $58.6 million in revenue from resilient royalties portfolio

06 May 2026 Form 4: DiPaolo Mark, Director

Received 9,786 shares as a grant or award · Granted 10,000 Non-statutory Stock Option

06 May 2026 Form 4: Raifeld Pavel, Director

Received 126,646 shares as a grant or award · Granted 312,500 Non-statutory Stock Option

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support